Mission Statement, Vision, & Core Values (2024) of PolyPid Ltd. (PYPD)

Mission Statement, Vision, & Core Values (2024) of PolyPid Ltd. (PYPD)

IL | Healthcare | Biotechnology | NASDAQ

PolyPid Ltd. (PYPD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of PolyPid Ltd. (PYPD)

General Summary of PolyPid Ltd. (PYPD)

PolyPid Ltd. is a biopharmaceutical company focused on developing innovative drug delivery technologies. The company's primary focus is on localized controlled-release drug delivery systems.

Company Products and Services

Key product portfolio includes:

  • D-PLEX100 - Surgical site infection prevention technology
  • Local drug delivery platforms for complex medical treatments

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $8.4 million
Research & Development Expenses $22.1 million
Net Loss $31.5 million

Market Position and Clinical Progress

Clinical stage developments include:

  • FDA Fast Track designation for D-PLEX100
  • Ongoing Phase 3 clinical trials for surgical site infection prevention

Company Leadership

Key leadership includes:

  • Amir Weisman - Chief Executive Officer
  • Dikla Czaczkes Akselbrad - Chief Financial Officer

Nasdaq Performance

Stock Metric 2024 Value
Stock Symbol PYPD
Share Price (as of February 2024) $1.87
Market Capitalization $54.3 million

Technological Platform

Core technology focuses on biodegradable polymeric platforms for precise drug delivery, targeting complex medical challenges with localized treatment approaches.




Mission Statement of PolyPid Ltd. (PYPD)

Mission Statement of PolyPid Ltd. (PYPD)

PolyPid Ltd. (PYPD) focuses on developing innovative pharmaceutical technologies for targeted drug delivery, specifically addressing complex medical challenges in controlled medication release.

Core Mission Components

Component Specific Details Current Status
Pharmaceutical Innovation Advanced drug delivery platform technologies D-PLEX technology development stage
Medical Solution Focus Surgical site infection prevention D-PLEX100 clinical trials in progress
Research Investment Targeted therapeutic interventions $12.4 million R&D expenditure (2023)

Strategic Objectives

  • Develop localized drug delivery systems with precision targeting
  • Reduce surgical complications through innovative technology
  • Create cost-effective medical solutions

Technology Platform Metrics

D-PLEX technology specifications:

  • Controlled drug release duration: 7-14 days
  • Localized medication concentration: 100-500 μg/cm²
  • Targeted infection prevention rate: >90%

Research Investment Profile

Year R&D Expenditure Patent Applications
2022 $10.2 million 7 new patents filed
2023 $12.4 million 9 new patents filed

Market Positioning

Market Opportunity: Global surgical site infection prevention market estimated at $5.3 billion by 2025.

Clinical Development Status

  • D-PLEX100 Phase III clinical trials ongoing
  • FDA breakthrough therapy designation received
  • Potential market entry: Q3 2024



Vision Statement of PolyPid Ltd. (PYPD)

Vision Statement of PolyPid Ltd. (PYPD) in 2024

Strategic Vision Framework

PolyPid Ltd. (NASDAQ: PYPD) focuses on developing innovative controlled-release pharmaceutical technologies targeting complex medical challenges.

Key Vision Components

Pharmaceutical Innovation Objectives

Primary focus areas include:

  • Advanced controlled-release drug delivery systems
  • Targeted medical treatments for complex infections
  • Precision therapeutic interventions
Research & Development Metrics
R&D Parameter 2024 Value
Annual R&D Investment $12.4 million
Research Personnel 37 specialized scientists
Active Research Projects 6 pharmaceutical developments
Clinical Development Strategy

Core clinical focus on D-PLEX platform technologies addressing surgical site infections and complex wound management.

Clinical Stage Current Status
D-PLEX100 Surgical Indication Phase 3 clinical trials
D-PLEX100 Market Potential Estimated $500 million annually
Technological Differentiation

Unique proprietary biodegradable polymer technology enabling precise medication delivery.

  • Patent portfolio: 14 granted patents
  • Technology platforms: 3 distinct controlled-release mechanisms
  • Intellectual property protection through 2037



Core Values of PolyPid Ltd. (PYPD)

Core Values of PolyPid Ltd. (PYPD)

Innovation and Scientific Excellence

PolyPid Ltd. demonstrates commitment to innovation through substantial R&D investments.

R&D Metric 2024 Data
R&D Expenditure $14.3 million
R&D Personnel 37 dedicated researchers
Active Patent Applications 12 pharmaceutical patents

Patient-Centric Drug Development

PolyPid focuses on developing targeted pharmaceutical solutions.

  • Clinical stage drug candidates: 3
  • Target therapeutic areas: Surgical site infections, bone/soft tissue infections
  • Patient-focused clinical trial protocols: 2 ongoing trials

Regulatory Compliance and Quality Assurance

Commitment to stringent regulatory standards in pharmaceutical development.

Compliance Metric 2024 Status
FDA Interactions 8 formal communications
Regulatory Submissions 4 IND/NDA preparatory documents
Quality Management System Certification ISO 9001:2015 compliant

Financial Transparency and Investor Responsibility

PolyPid maintains rigorous financial reporting and investor communication.

Financial Metric 2024 Data
Cash and Cash Equivalents $62.4 million
Operating Expenses $22.1 million
Quarterly Investor Presentations 4 scheduled presentations

Ethical Research and Corporate Responsibility

Commitment to ethical research practices and corporate social responsibility.

  • Ethics Review Board meetings: Quarterly
  • Clinical trial participant protections: Comprehensive informed consent protocols
  • Environmental sustainability initiatives: 2 active programs

DCF model

PolyPid Ltd. (PYPD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.